Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification...

Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T₅₀, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To assess this hypothesis we measured T₅₀ in kidney transplant recipients participating in a randomized study comparing paricalcitol versus no treatment during the first year after kidney transplantation.

Stored serum samples from 76 kidney transplant recipients (paricalcitol n = 37, no treatment n = 39) were analyzed. Analyses were performed at inclusion (8 weeks after transplantation) and repeated one year after transplantation.

There were no statistically significant differences in T₅₀ between the paricalcitol and placebo groups, neither at baseline (p = 0.56) nor at 1 year (p = 0.61). Also, there were no significant changes in T₅₀ over time in either group or when pooling all data (p <  0.20). In multivariate regression analysis, out of 16 potentially relevant covariates, comprising clinical and biochemical parameters, only plasma PTH and T₅₀ at baseline were significantly correlated to T₅₀ after one year. (p <  0.03 and p < 0.01, respectively).

Calcium propensity measured as T₅₀ score remained unchanged with paricalcitol treatment in kidney transplant recipients, and was not changed over time during the study period of one year.

ClinicalTrials.gov, NCT01694160 , registered 23 September 2012.